Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk
Our commission was to assess the effectiveness, safety and economic consequences of broadening the indication for TAVI to encompass patients with severe aortic stenosis and intermediate operative risk
Heart failure due to aortic stenosis represents an increasing health problem amongst the elderly. Treatment of severe aortic stenosis primarily involves valve replacement surgery. Transcatheter aortic valve implantation (TAVI) is an alternative to traditional open-hearth surgery. In Norway, TAVI was introduced in 2008 as an option for selected patients at high surgical risk and patients who otherwise are unsuitable candidates for traditional heart surgery. The use of TAVI has been limited by uncertainty related to risk of adverse events and increased costs. The use of TAVI has gradually increased, and TAVI is now suggested as an option also for patients at intermediate surgical risk.
In April 2017, The Norwegian Institute of Public Health was commissioned by the National System for Managed Introduction of New Health Technologies to assess the effectiveness, safety and economic consequences of broadening the indication for TAVI to encompass patients with severe aortic stenosis and intermediate operative risk.
About the project
- Project number Nye Metoder ID2016_076
- Start 05/2017
- End 02/2018
- Project owner/project manager Folkehelseinstituttet
- Project description TAVI Prosjektplan 2017.pdf
- Project manager
- Participant FHI
Dahle, Gry, thoraxkirurg, overlege thoraxkirurgisk avdeling OUS; Bjørnerheim, Reidar, Dr.med. kardiolog, seksjonsoverlege, ekkolaboratoriet OUS; Færestrand, Svein Dr. med, prof. emeritius, kardiolog; Widmark, Anders, Statens Strålevern